Bone Cancer Education

Pancreas, IMM1104-101

A phase 1/2a open label study of IMM-1-104 in Participants with Un-resectable or Metastatic Previously Treated Pancreatic Cancer or RAS Mutated NSCLC or Melanoma

Melanoma, 20210031 “Amegan Zinnia”

The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.

Melanoma, IMM1104-101

A phase 1/2a open label study of IMM-1-104 in Participants with Un-resectable or Metastatic Previously Treated Pancreatic Cancer or RAS Mutated NSCLC or Melanoma

Lung, IMM1104-101

A phase 1/2a open label study of IMM-1-104 in Participants with Un-resectable or Metastatic Previously Treated Pancreatic Cancer or RAS Mutated NSCLC or Melanoma

Lung, D798AC00001 “eVOLVE-Lung02”

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 < 50%.

Breast, A191901

Optimizing endocrine therapy through motivational interviewing and text interventions

Breast, NRG-CC011

This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.

Advance Directives for New York State

Patient Newsletter 2024 June

Pages